Cochlear Targets Adult-Care Growth After Challenging Year
Cochlear’s chair said FY26 performance fell below expectations, citing healthcare capacity constraints, insurance delays, reimbursement changes and other operating pressures. The company is accelerating cost reductions and a more scalable operating model while expanding clinician-led referral pathways to reach more adults with severe hearing loss; its guidelines are being implemented across 25 countries. The excerpt also says Professor Ian Meredith will join the board as an independent non-executive director in December.
Closing price · 2026-10-26: $141.82 · -3.40%